Lercanidipino Sandoz

Lercanidipine, the active ingredient in Lercanidipino Sandoz, is a calcium channel blocker presented as an oral tablet for oral use. It is available in standard dosage strengths for convenient once‑daily dosing and treats hypertension in adult patients by relaxing vascular smooth muscle and lowering peripheral resistance.

GNH USA supplies Lercanidipino Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support and consistent product quality to meet global healthcare needs through established distribution networks.

Lercanidipine is a calcium channel blocker indicated for the management of hypertension.

- Essential hypertension: lowers sustained high blood pressure by relaxing arterial smooth muscle, improving cardiovascular outcomes. - Renal hypertension: assists in controlling blood pressure in patients with kidney‑related hypertension by reducing systemic vascular resistance. - Isolated systolic hypertension: helps manage elevated systolic pressure in older adults through arterial vasodilation.

Lercanidipine may cause a range of adverse reactions, which are generally categorized by frequency.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Flushing: sensation of warmth and redness, usually short‑lived. - Peripheral edema: swelling of ankles or lower limbs. - Dizziness: may occur upon standing, related to blood pressure changes. - Tachycardia: increased heart rate in some patients. - Gastrointestinal discomfort: mild nausea or abdominal pain.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Myocardial infarction: rare occurrence of heart attack. - Hepatic injury: signs of liver dysfunction such as jaundice. - Anaphylactic reaction: life‑threatening allergy with rash, swelling, or breathing difficulty. - Angio‑edema: swelling of face, lips, or tongue. - Cardiac arrhythmias: irregular heart rhythms in susceptible individuals.

When prescribing Lercanidipine, clinicians should consider several safety aspects. - Blood pressure monitoring: regularly assess to avoid excessive hypotension. - Hepatic impairment: use with caution in patients with moderate to severe liver disease. - Concomitant antihypertensives: adjust doses to prevent additive blood pressure lowering. - Pregnancy: safety not established; avoid unless clearly needed. - Patient counseling: advise on rising slowly from sitting to reduce dizziness. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Lercanidipine can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin): may increase plasma levels and risk of hypotension. - Grapefruit juice: can elevate drug concentration, leading to excessive vasodilation. - Other potent antihypertensives: may cause additive blood pressure reduction.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce effectiveness. - Diuretics: monitor electrolytes and blood pressure. - Beta‑blockers: watch for combined bradycardia or hypotension. - NSAIDs: may blunt antihypertensive effect. - Alcohol: can enhance dizziness and hypotensive response.